header logo image header logo text
Downloads Login
Research
General Information
ZIRC
ZFIN ID: ZDB-FISH-150901-21121
Fish name: la2Tg
Genotype: la2Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by la2Tg
Human Disease Conditions Citations
nephrotic syndrome chemical treatment by environment: doxorubicin Eneman et al., 2017
GENE EXPRESSION
Gene expression in la2Tg
PHENOTYPE
Phenotype in la2Tg
Phenotype Conditions Figures
caudal hematopoietic tissue hematopoietic stem cell decreased amount, abnormal standard conditions Fig. 3 from Oo et al., 2017
glomerular filtration process quality, abnormal chemical treatment by environment: doxorubicin Fig. 5 with image from Eneman et al., 2017
hematopoietic stem cell decreased amount, abnormal chemical treatment by environment: 17beta-estradiol Fig. 1 with imageFig. 7 with image from Carroll et al., 2014
hematopoietic stem cell increased amount, abnormal chemical treatment by environment: estrogen receptor antagonist Fig. 7 with image from Carroll et al., 2014
hemostasis increased duration, abnormal contusion: caudal fin Fig. 4 from Lin et al., 2017
hemostasis increased duration, abnormal perforation: blood vessel Fig. 4 from Lin et al., 2017
intermediate cell mass of mesoderm hematopoietic stem cell decreased amount, abnormal chemical treatment: cannabinoid receptor agonist Fig. 2 with image from Esain et al., 2015
intermediate cell mass of mesoderm hematopoietic stem cell decreased amount, abnormal chemical treatment: 3-[7-(2,4-dimethoxyphenyl)-1,4-thiazepan-5-ylidene]-6-methylpyran-2,4-dione Fig. 6 with image from Esain et al., 2015
intermediate cell mass of mesoderm hematopoietic stem cell decreased amount, abnormal chemical treatment: cannabinoid receptor agonist, chemical treatment: 3-[7-(2,4-dimethoxyphenyl)-1,4-thiazepan-5-ylidene]-6-methylpyran-2,4-dione Fig. 6 with image from Esain et al., 2015
intermediate cell mass of mesoderm hematopoietic stem cell increased amount, abnormal chemical treatment: cannabinoid receptor agonist, chemical treatment: EC 2.7.11.* (protein-serine/threonine kinase) inhibitor Fig. 5 with image from Esain et al., 2015
intermediate cell mass of mesoderm hematopoietic stem cell increased amount, abnormal chemical treatment: cannabinoid receptor agonist, chemical treatment: NS-398 Fig. 5 with image from Esain et al., 2015
intermediate cell mass of mesoderm hematopoietic stem cell increased amount, abnormal chemical treatment: cannabinoid receptor agonist Fig. 2 with imageFig. 5 with imageFig. 6 with image from Esain et al., 2015
pericardium edematous, abnormal chemical treatment by environment: doxorubicin Fig. 5 with imageFig. 8 from Eneman et al., 2017
thrombocyte amount, normal chemical treatment by environment: doxorubicin Fig. 7 with image from Eneman et al., 2017
thrombocyte decreased amount, abnormal chemical treatment: pharmaceutical Fig. 6 with image from Bielczyk-Maczyńska et al., 2014
thrombocyte decreased amount, abnormal chemical treatment by environment: TG101209 Fig. 3 from Lin et al., 2017
whole organism dead, abnormal chemical treatment by environment: doxorubicin Fig. 5 with imageFig. 8 from Eneman et al., 2017
whole organism adcyap1a expression decreased amount, abnormal chemical treatment by environment: doxorubicin Fig. S2 from Eneman et al., 2017
whole organism nphs1 expression decreased amount, abnormal chemical treatment by environment: doxorubicin Fig. 5 with image from Eneman et al., 2017
whole organism morphology, abnormal chemical treatment by environment: doxorubicin Fig. 5 with imageFig. 8 from Eneman et al., 2017

CITATIONS  (92)